Peptide News Digest

#Advisory-Vote

3 stories

Regulatory · View digest

Two-Day Session Synthesis: 6 of 7 Research Peptides Recommended by the FDA Pharmacy Compounding Advisory Committee for the Section 503A Bulks List Across Thursday July 23 and Friday July 24, 2026, With Only Emideltide (DSIP) Failing to Secure a Majority; All Six Wins Override the FDA Career-Staff Position and Represent the Broadest Advisory Endorsement of Compounding-Channel Peptides in the Committee's History; STAT News and Time Magazine Frame the Outcome as a Win for HHS Secretary Robert F. Kennedy Jr. and Continued Rulemaking Timeline of 6-18 Months Still Applies Before Actual Compounding-Pharmacy Access Changes

The two-day FDA Pharmacy Compounding Advisory Committee (PCAC) session closed Friday July 24, 2026 with 6 of 7 research peptides recommended for the Section 503A Bulks List. Day 1 wins: BPC-157 (8-6-1), KPV (8-6-1), TB-500 (8-6), MOTS-c (7-5-2). Day 2 wins: Semax (8-5), Epitalon (7-4). Day 2 rejection: Emideltide/DSIP. Every one of the 6 wins overrode the FDA career-staff briefing documents that recommended against adding any of the seven peptides. STAT News, Time Magazine, NPR, ABC News, Bloomberg, US News, The Hill, and Washington Times converged on the framing that HHS Secretary Robert F. Kennedy Jr.'s peptide-access push cleared a substantive advisory threshold. Panel composition itself was a substantive factor: eight new PCAC members were named June 29, with at least seven documented to have peptide-industry ties per STAT News. What still has to happen before actual compounding-pharmacy access changes: FDA leadership must review each vote, decide whether to accept it, publish a proposed rule in the Federal Register, run a 60-90 day public comment period, respond to comments, and publish a final rule with an effective date. Rulemaking typically takes 6-18 months per substance from the date the FDA decides to act.

Regulatory · View digest

BREAKING: FDA Pharmacy Compounding Advisory Committee (PCAC) Narrowly Votes 8-6 With 1 Abstention on Thursday July 23, 2026 to Recommend Adding BPC-157 to the Section 503A Bulks List; the First PCAC Recommendation to Add a Popular Research Peptide to the Compounding Pathway, Overriding FDA Career-Staff Briefing Documents That Recommended Against Inclusion; Committee's Advisory Vote Is Non-Binding and Typically Followed by FDA; Formal Rulemaking to Implement Would Take Six to Eighteen Months

The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention on Thursday July 23, 2026 to recommend adding BPC-157 to the Section 503A Bulk Drug Substances List, in a win for HHS Secretary Robert F. Kennedy Jr.'s peptide deregulation agenda. The narrow vote overrode FDA career-staff briefing documents released June 29-30 that recommended against adding any of the seven peptides under review, citing immunogenicity concerns, heavy-metal and microbial contamination in samples pulled from the compounding channel, mislabeled contents, and thin 503A historical use. The vote sequencing during the Thursday session followed extensive public comment; Hims Chief Medical Officer Dr. Anant Vinjamoori argued during his testimony that a no vote would push peptides deeper into an unregulated gray market rather than end the underlying demand. PCAC recommendations are advisory and non-binding; the FDA typically follows them, and formal rulemaking to implement the recommendation would take approximately 6 to 18 months. Panel composition is a significant contextual factor: before the meeting, more than a half-dozen new members with documented ties to the peptide industry were added to the PCAC.

Regulatory · View digest

PCAC Also Votes 8-6 With 1 Abstention on Thursday July 23 to Recommend Adding KPV (Lys-Pro-Val Tripeptide) to the 503A Bulks List, the Second Day-One Win for Broader Peptide Access; KPV Is an α-MSH-Derived Tripeptide Studied for Anti-Inflammatory Effects in the Gut and Nominated for Ulcerative Colitis and Inflammatory Conditions; PCAC Will Vote Later Thursday on TB-500 and MOTS-c to Complete Day 1 Before Reconvening Friday July 24 for the DSIP/Emideltide, Semax, and Epitalon Session

The FDA Pharmacy Compounding Advisory Committee (PCAC) voted identically 8-6 with 1 abstention on Thursday July 23, 2026 to recommend adding KPV to the Section 503A Bulk Drug Substances List. KPV is a tripeptide (lysine-proline-valine) derived from alpha-melanocyte-stimulating hormone (α-MSH) with anti-inflammatory activity documented primarily in preclinical inflammatory bowel disease and colitis models. It was nominated for ulcerative colitis and inflammatory conditions. FDA career staff recommended against adding KPV, noting thin human clinical trial evidence and 503A historical use questions. The 8-6 KPV vote matches the identical BPC-157 vote earlier in the session and reflects a coordinated panel disposition to override the FDA staff position on the two Day-1 morning peptides. The PCAC session continues Thursday afternoon with votes on TB-500 (thymosin beta-4 fragment for wound healing and tissue repair) and MOTS-c (mitochondrial-derived peptide for obesity and metabolic disease). The Friday July 24 session covers DSIP/Emideltide (delta sleep-inducing peptide), Semax (heptapeptide ACTH analog for cerebral ischemia and cognition), and Epitalon (tetrapeptide for anti-aging and insomnia).